| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 0.0 | 0.0 | 0.0 |
| Other income | 0.1 | 0.1 | 1.1 |
| Total income | 0.1 | 0.1 | 1.1 |
| Profit before exceptional items & tax | -0.0 | 0.1 | 0.9 |
| Profit before tax | -0.0 | 0.1 | 0.9 |
| Net profit | -0.1 | -0.0 | 0.7 |
| Operating margin | 0.0% | 100.0% | 81.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Operating profit, year on year | +50.00% |
|---|
BSE results filing, NSE: BACPHAR. Figures extracted from the filing.
Bacil Pharma Ltd: key numbers
- Share price
- ₹19.36
- Market cap
- ₹27.79 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹1.56 Cr
- P/E (TTM)
- 44.0×Sector 46.1×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bacil Pharma Ltd
All →Bacil Pharma Other Announcement
Bacil Pharma Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Regulation 31.
Bacil Pharma Management Change
Mr. Dikshant Singh Panwar has resigned as Whole-Time Company Secretary and Compliance Officer of Bacil Pharma Limited, effective October 8, 2026.
Bacil Pharma Board Meeting Date
Bacil Pharma will hold a board meeting on October 14, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026.
Bacil Pharma Annual Report
Bacil Pharma Limited submitted its 39th Annual Report for FY 2025-26. The Annual General Meeting is scheduled for September 23, 2026, via video conferencing.
Bacil Pharma Annual General Meeting
Bacil Pharma Limited has announced book closure dates from September 17 to September 23, 2026, for its 39th Annual General Meeting.
Bacil Pharma Board Meeting Date
Bacil Pharma Limited has scheduled a board meeting for August 29, 2026, to discuss and approve the notice and scheduling of its 39th Annual General Meeting.